A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

1600461186372COR3001-NCT06662786OpenA Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer61186372COR3001NCT06662786IndustrialAdultTreatmentIIIOtherWeinberg, BenjaminGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>